Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925312 | 1.00 | BPTF (0.43) | BPTFSLC18A3SIGMAR1KDM1AMAOA | |
| SCHEMBL7076302 | 0.95 | CYP11B2 (0.44) | BPTFSLC18A3SIGMAR1KDM1AMAOA | |
| SCHEMBL19122346 | 0.85 | SLC18A3 (0.50) | SLC18A3SIGMAR1KDM1AMAOAMAOB | |
| SCHEMBL16422679 | 0.76 | HTR2C (0.41) | KDM1ACHRNB4CHRNA3 | |
| SCHEMBL233570 | 0.74 | SLC18A3 (0.58) | BPTFSLC18A3SIGMAR1KDM1AMAOA | |
| SCHEMBL8660684 | 0.74 | MAOA (0.55) | SLC18A3SIGMAR1KDM1AMAOAMEN1 | |
| SCHEMBL3870080 | 0.74 | MAOA (0.55) | SLC18A3SIGMAR1KDM1AMAOAMEN1 | |
| SCHEMBL3870077 | 0.74 | MAOA (0.55) | SLC18A3SIGMAR1KDM1AMAOAMEN1 | |
| SCHEMBL10153406 | 0.73 | BPTF (0.42) | BPTFSLC18A3SIGMAR1KDM1AMAOA | |
| Hydrochloric Acid SCHEMBL557175 | 0.72 | SLC18A3 (0.56) | BPTFSLC18A3SIGMAR1KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-04-10 | — | — | US | disclosed |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-09-24 | — | — | US | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11369606-B2 | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-28 | — | — | US | disclosed |
| US-20220047593-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-17 | — | — | US | disclosed |
| US-20200138813-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-20200138814-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-07 | — | — | US | disclosed |
| EP-2344470-B1 | 3-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2430022-A1 | 1,2,3-TRIAZOLO Ý4,3-A¨PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Janssen Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110306642-A1 | 3-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2011-12-15 | — | — | US | disclosed |
| EP-2344470-A1 | 3-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010130424-A9 | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010025890-A1 | 3-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-03-11 | — | — | WO | disclosed |
| US-6096755-A | N-substituted azabicycloalkane derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-01 | — | — | US | disclosed |
| EP-0731802-A1 | N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES AS NEUROLEPTIKA ASF | BASF AKTIENGESELLSCHAFT (DE) | 1996-09-18 | — | — | EP | disclosed |
| EP-0728136-A1 | N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995015327-A1 | N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES AS NEUROLEPTIKA ASF | BASF AKTIENGESELLSCHAFT (DE) | 1995-06-08 | — | — | WO | disclosed |
| WO-1995013279-A1 | N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306642-A1 | 3-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM1, GRIN2C | BPTF 3509/4885SLC18A3 545/4885SIGMAR1 687/4885 |
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | BPTF 2674/4885SLC18A3 2156/4885SIGMAR1 394/4885 |
| US-20220047593-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | BPTF 2044/4885SLC18A3 90/4885SIGMAR1 131/4885 |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, NR1I2 | BPTF 2674/4885SLC18A3 2156/4885SIGMAR1 394/4885 |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | BPTF 2674/4885SLC18A3 2156/4885SIGMAR1 394/4885 |
| US-20200138813-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | BPTF 2044/4885SLC18A3 90/4885SIGMAR1 131/4885 |
| US-11369606-B2 | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | GRM2, GRIN2A, GRIK2 | BPTF 2044/4885SLC18A3 90/4885SIGMAR1 131/4885 |
| US-20200138814-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | BPTF 2044/4885SLC18A3 90/4885SIGMAR1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.